Our preliminary results indicate increases in NOX4 expression in IPF epithelia that can be reduced by pirfinidone, nintedanib, as well as saracatinib, although their effects on redox homeostasis genes was quite variable between individual patients with IPF. Here, NOX4 is linked to idiopathic pulmonary fibrosis.